INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 41h ago
HOUSE PTR1h ago
SEC 13F1h ago
ROBINHOOD CHAIN1h ago
Public company

ACRSAclaris Therapeutics, Inc.

CIK 0001557746

EDGAR filingsOpen in network
Disclosed transactions18
Buys / sells0 / 0
Max Insider Score21
Connections5with evidence

ACRS · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
9
HW
Hall Jesse WayneChief Medical Officer
ACRSAclaris Therapeutics, Inc.
Option exercise
M—
36.4K sh
May 1, 2026May 5, 2026
traded May 1, 2026
+4dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 4, 2026
  • ← Insider ofevidence
    Kolbeck Roland WilhelmChief Scientific Officer · Feb 6, 2026
  • ← Insider ofevidence
    Hall Jesse WayneChief Medical Officer · Feb 6, 2026
  • ← Insider ofevidence
    Balthaser KevinChief Financial Officer · Feb 5, 2026
21
HW
Hall Jesse WayneChief Medical Officer
ACRSAclaris Therapeutics, Inc.
Tax withholding
F
$41K
9,330 sh
May 1, 2026
May 5, 2026
traded May 1, 2026
+4d
SEC FORM 4

Evidence

21
HW
Hall Jesse WayneChief Medical Officer
ACRSAclaris Therapeutics, Inc.
Option exercise
M—
36.4K sh
May 1, 2026May 5, 2026
traded May 1, 2026
+4dSEC FORM 4

Evidence

15
KW
Kolbeck Roland WilhelmChief Scientific Officer
ACRSAclaris Therapeutics, Inc.
Grant or award
A—
95.7K sh
Feb 2, 2026Feb 6, 2026
traded Feb 2, 2026
+4dSEC FORM 4

Evidence

15
HW
Hall Jesse WayneChief Medical Officer
ACRSAclaris Therapeutics, Inc.
Grant or award
A—
98.1K sh
Feb 2, 2026Feb 6, 2026
traded Feb 2, 2026
+4dSEC FORM 4

Evidence

15
DM
Davis Hugh M.Director, President and COO
ACRSAclaris Therapeutics, Inc.
Grant or award
A—
96.1K sh
Feb 2, 2026Feb 6, 2026
traded Feb 2, 2026
+4dSEC FORM 4

Evidence

15
DM
Davis Hugh M.Director, President and COO
ACRSAclaris Therapeutics, Inc.
Grant or award
A—
336.3K sh
Feb 2, 2026Feb 6, 2026
traded Feb 2, 2026
+4dSEC FORM 4

Evidence

15
BK
Balthaser KevinChief Financial Officer
ACRSAclaris Therapeutics, Inc.
Grant or award
A—
99.1K sh
Feb 2, 2026Feb 6, 2026
traded Feb 2, 2026
+4dSEC FORM 4

Evidence

15
BK
Balthaser KevinChief Financial Officer
ACRSAclaris Therapeutics, Inc.
Grant or award
A—
346.8K sh
Feb 2, 2026Feb 6, 2026
traded Feb 2, 2026
+4dSEC FORM 4

Evidence

15
KW
Kolbeck Roland WilhelmChief Scientific Officer
ACRSAclaris Therapeutics, Inc.
Grant or award
A—
334.9K sh
Feb 2, 2026Feb 6, 2026
traded Feb 2, 2026
+4dSEC FORM 4

Evidence

15
HW
Hall Jesse WayneChief Medical Officer
ACRSAclaris Therapeutics, Inc.
Grant or award
A—
343.3K sh
Feb 2, 2026Feb 6, 2026
traded Feb 2, 2026
+4dSEC FORM 4

Evidence

21
DM
Davis Hugh M.Director, President and COO
ACRSAclaris Therapeutics, Inc.
Option exercise
M—
18.7K sh
Feb 3, 2026Feb 5, 2026
traded Feb 3, 2026
+2dSEC FORM 4

Evidence

21
DM
Davis Hugh M.Director, President and COO
ACRSAclaris Therapeutics, Inc.
Option exercise
M—
18.7K sh
Feb 3, 2026Feb 5, 2026
traded Feb 3, 2026
+2dSEC FORM 4

Evidence

13
BK
Balthaser KevinChief Financial Officer
ACRSAclaris Therapeutics, Inc.
Option exercise
M—
22.0K sh
Feb 3, 2026Feb 5, 2026
traded Feb 3, 2026
+2dSEC FORM 4

Evidence

9
BK
Balthaser KevinChief Financial Officer
ACRSAclaris Therapeutics, Inc.
Tax withholding
F$22K
6,449 sh
Feb 3, 2026Feb 5, 2026
traded Feb 3, 2026
+2dSEC FORM 4

Evidence

21
BK
Balthaser KevinChief Financial Officer
ACRSAclaris Therapeutics, Inc.
Option exercise
M—
22.0K sh
Feb 3, 2026Feb 5, 2026
traded Feb 3, 2026
+2dSEC FORM 4

Evidence

9
DM
Davis Hugh M.Director, President and COO
ACRSAclaris Therapeutics, Inc.
Option exercise
M—
26.8K sh
Dec 2, 2025Dec 4, 2025
traded Dec 2, 2025
+2dSEC FORM 4

Evidence

21
DM
Davis Hugh M.Director, President and COO
ACRSAclaris Therapeutics, Inc.
Option exercise
M—
26.8K sh
Dec 2, 2025Dec 4, 2025
traded Dec 2, 2025
+2dSEC FORM 4

Evidence

  • ← Insider ofevidence
    Davis Hugh M.Director, President and COO · Dec 4, 2025